IASLC Global Survey on Biomarker Testing in Lung Cancer – 2024 Update

Biomarker testing is essential in lung cancer care, allowing for personalized diagnosis and treatment. Survey closes March 23, 2024.
biomarker survey header

Biomarker testing is essential in lung cancer care, allowing for personalized diagnosis and treatment. By pinpointing specific genetic mutations, it enables multidisciplinary cancer care teams to select the most effective targeted therapies, improving outcomes and minimizing side effects. As cancer care advances toward precision medicine, the importance of biomarker testing in guiding treatment decisions grows significantly; However, the global adoption of comprehensive biomarker testing remains inadequate.

medical survey

To enhance our understanding of the current landscape surrounding biomarker testing in patients diagnosed with lung cancer globally, we urge IASLC members, healthcare practitioners, and other stakeholders to participate in this survey.

Survey Open from February 16 - March 23, 2024.

Biomarkers in Lung Cancer: Barriers to Implementation

Image
Biomarkers in Lung Cancer: Barriers to Implementation

LCC in English

Host Dr. Stephen Liu discusses the importance of this survey and some of the barriers to biomarker testing with Dr. Debora Bruno, Dr. Rami Manochakian, and Dr. Matthew Smeltzer.
Image
LCC in Mandarin Chinese: Barriers to Biomarker Testing

LCC in Mandarin Chinese

Host Dr. Chunxia Su moderates a discussion in Mandarin about biomarker testing with Dr. Bo Zhu and Dr. Yuan Li.
Image
LCC in Japanese: Barriers to Biomarker Testing

LCC in Japanese

Host Dr. Misako Nagasaka leads a discussion in Japanese about biomarker testing with Dr. Terufumi Kato and Dr. Masahiro Tsuboi.
Image
LCC in Cantonese Chinese: Barriers to Biomarker Testing

LCC in Cantonese Chinese

Host Dr. Sally Lau leads a discussion in Cantonese about barriers to biomarker testing with Dr. Herbert Loong and Dr. Molly Li.
Image
LCC in Spanish: Barriers to Biomarker Testing

LCC in Spanish

Dr. Narjust Florez discusses the importance of this survey and some of the barriers to biomarker testing in Spanish with Dr. Ivy Riano and Dr. Teresa Gorría.
Image
LCC in Portuguese: Barriers to Biomarker Testing

LCC in Portuguese

Host Dr. Clarissa Mathias leads a discussion in Portuguese about biomarker testing with Dr. Vladmir Lima and Dr. Aknar Calabrich.
Image
LCC in French Canadian: Barriers to Biomarker Testing

LCC in French Canadian

Host Dr. Norman Blais moderates a discussion about biomarker testing with Dr. Arielle Elkrief and Dr. Nicolas Marcoux.
Image
LCC in French: Barriers to Biomarker Testing

LCC in French

Host Dr. Alfredo Addeo discussed barriers to biomarker testing in French with Dr. Solange Peters and Dr. Maurice Perol.
barriers graphic

To better understand barriers to implementation and utilization of biomarker testing globally, the IASLC conducted a survey in 2017 to assess current practices and barriers to uptake of biomarker testing globally. Since the publication of these results in 2018 there have been several therapeutic breakthroughs:

  1. Approvals for advanced lung cancer treatments targeting MET, RET, KRAS, HER2, and NTRK mutations.
  2. Growing regulatory endorsements for ICI-based treatments in stage II-III disease.
  3. The authorization of osimertinib for resectable lung cancer.

With these advancements, it is the ideal time to conduct a new survey to assess the current landscape of biomarker testing globally.

This updated survey will capture the evolving trends in biomarker testing since our last assessment, shed light on the current momentum toward adopting or intensifying NGS testing, and delve into the challenges faced by various providers and health systems. Our objective is to leverage this data to craft a comprehensive resource guide on NGS testing implementation.

This survey is in partnership with the IASLC Partners for Thoracic Cancer Care.

IPTCC logo